title: Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections.
abstract: OBJECTIVE
  To determine the incidence of rhegmatogenous retinal detachments (RD) after intravitreal injection in six high-volume centres.
  
  
  METHODS
  A consecutive, interventional, multicenter case series measured the incidence of RD in patients receiving intravitreal anti-VEGF. A total of 35 942 intravitreal anti-VEGF injections (the number of the injections determined by review of injection log books over a 3 year period) were performed under sterile conditions with the patient in a supine position. Injections were given 3.5-4.0 mm behind the limbus in a tunnelled fashion.
  
  
  RESULTS
  During 36 consecutive months, five RD were reported, between 2 and 6 days after the injection. Of the affected eyes, four were myopic -1.75 to -5.5 dpt. The incidence rate of rhegmatogenous RD was 0.013% (5/35 942) per injection.
  
  
  CONCLUSIONS
  The incidence of RD in our community setting was very low (1 per 7188 injections). All RD occurred during the early postoperative period. The risks of RD can be minimized by a careful injection technique.
authors.affiliation: Department of Ophthalmology, University of Bonn, Germany. meyer_eye@yahoo.com
authors.forename: Carsten H
authors.initials: CH
authors.lastname: Meyer
authors.forename: Stephan
authors.initials: S
authors.lastname: Michels
authors.forename: Eduardo B
authors.initials: EB
authors.lastname: Rodrigues
authors.forename: Annette
authors.initials: A
authors.lastname: Hager
authors.forename: Stefan
authors.initials: S
authors.lastname: Mennel
authors.forename: Jörg C
authors.initials: JC
authors.lastname: Schmidt
authors.forename: Hans-Martin
authors.initials: HM
authors.lastname: Helb
authors.forename: Michel E
authors.initials: ME
authors.lastname: Farah
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D005260:Female; D006801:Humans; D007049:Iatrogenic Disease / Q000453:epidemiology*; D015994:Incidence; D058449:Intravitreal Injections / Q000009:adverse effects*; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000453:epidemiology* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000188:drug therapy; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab